Neuren Pharmaceuticals Ltd
NEU
Company Profile
Business description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Contact
697 Burke Road
Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920480
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.30 | 125.30 | -1.44% |
| CAC 40 | 7,697.29 | 28.91 | -0.37% |
| DAX 40 | 22,447.08 | 206.78 | -0.91% |
| Dow JONES (US) | 46,208.47 | 631.00 | 1.38% |
| FTSE 100 | 9,868.45 | 25.70 | -0.26% |
| HKSE | 25,063.71 | 681.24 | 2.79% |
| NASDAQ | 21,946.76 | 299.15 | 1.38% |
| Nikkei 225 | 52,252.28 | 736.79 | 1.43% |
| NZX 50 Index | 12,701.75 | 197.97 | -1.53% |
| S&P 500 | 6,581.00 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,379.40 | 125.20 | -1.47% |
| SSE Composite Index | 3,881.28 | 68.00 | 1.78% |